Taken together, targeting GSPT1 with a molecular glue degrader exhibitsstrong synergy with FLT3 inhibitors in FLT3-ITD-positive AML both in vitro andin vivo and represents a promising approach to enhance treatment efficacy inFLT3-ITD-mutated AML. Here, FLT3 is linked to acute myeloid leukemia.